Abstract figure legend Differences in cardiovascular function between appropriately grown (AG) and fetal growth restricted (FGR) infants after the cardiopulmonary transition at birth. AG infants typi....

A new study, led by experts at the University of Nottingham, has found that young people suffering from certain types of cancer, such as bone tumours, are experiencing lengthy times to diagnosis.

In some pre-clinical models, erythropoietin acts as a neuroprotective agent, which led to the performance of clinical trials to determine whether there was a positive impact on outcomes of the preterm. The latest study has just been published, and it is another high quality trial from the NICHD NRN, and Robin Ohls. The article starts with a questionable assertion, "Erythropoiesis-stimulating agents (ESAs) such as erythropoietin...have shown evidence for neuroprotection in preterm infants". I think if that was true, they would not have done this trial! In fact the references they give for that statement show a very variable impact on outcomes, the figure below is from a SR/MA which included only erythropoietin studies, eliminating a darbepoietin (a long acting EPO analogue) group in the second study by Robin Ohls et al (2014).

and ways to deal with it